4.7 Article

Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank

期刊

AMERICAN JOURNAL OF HUMAN GENETICS
卷 110, 期 10, 页码 1628-1647

出版社

CELL PRESS
DOI: 10.1016/j.ajhg.2023.09.001

关键词

-

向作者/读者索取更多资源

Pharmacogenomics is a crucial part of precision medicine. By analyzing genetic data from the UK Biobank, we estimated the pharmacogenomic frequencies in different biogeographic groups. The frequencies varied between each group. We also identified rare or seldom tested non-functional alleles that were previously overlooked. These estimated frequencies are disseminated through the Pharmacogenomics Knowledgebase, providing guidance for future research and clinical genetic testing.
Pharmacogenomics (PGx) is an integral part of precision medicine and contributes to the maximization of drug efficacy and reduction of adverse drug event risk. Accurate information on PGx allele frequencies improves the implementation of PGx. Nonetheless, curating such information from published allele data is time and resource intensive. The limited number of allelic variants in most studies leads to an underestimation of certain alleles.We applied the Pharmacogenomics Clinical Annotation Tool (PharmCAT) on an integrated 200K UK Biobank genetic dataset (N = 200,044). Based on PharmCAT results, we estimated PGx frequencies (alleles, diplotypes, phenotypes, and activity scores) for 17 pharmacogenes in five biogeographic groups: European, Central/South Asian, East Asian, Afro-Caribbean, and Sub-Saharan African. PGx frequencies were distinct for each biogeographic group. Even biogeographic groups with similar proportions of phenotypes were driven by different sets of dominant PGx alleles. PharmCAT also identified no-functionalleles that were rare or seldom tested in certain groups by previous studies, e.g., SLCO1B1*31 in the Afro-Caribbean (3.0%) and Sub-Saharan African (3.9%) groups.Estimated PGx frequencies are disseminated via the PharmGKB (The Pharmacogenomics Knowledgebase: www.pharmgkb.org). We demonstrate that genetic biobanks such as the UK Biobank are a robust resource for estimating PGx frequencies. Improving our understanding of PGx allele and phenotype frequencies provides guidance for future PGx studies and clinical genetic test panel design, and better serves individuals from wider biogeographic backgrounds.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据